Germany Decides On Added Benefit Of Gilead’s Veklury For COVID-19
Executive Summary
The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.
You may also be interested in...
Mexico Continues Reliance Strategy To Expand Drug Access
Mexico aims to speed up the registration of generics and biosimilars.
Belgium Aims To Drive Biologic Competition Through Tendering
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.
Companies Need EU Funding To Cover ‘Enormous Expenditure’ Of Complying With Revised GMP Rules
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.